Chester “Chip” Davis, Jr

Chester “Chip” Davis, Jr
Chester “Chip” Davis, Jr. is the President and Chief Executive Officer of the Association for Accessible Medicines (AAM), the nation’s leading trade association for manufacturers and distributors of generic prescription drugs, manufacturers of bulk active pharmaceutical chemicals and suppliers of other goods and services to the generic drug industry. Appointed to the position by the AAM Board in summer 2015, Chip is responsible for ensuring that the association fulfils its primary mission, which is to improve the lives of patients and consumers by providing timely access to safe, effective and affordable medicines. Prior to joining AAM, Chip most recently served …
Chester “Chip” Davis, Jr. is the President and Chief Executive Officer of the Association for Accessible Medicines (AAM), the nation’s leading trade association for manufacturers and distributors of generic prescription drugs, manufacturers of bulk active pharmaceutical chemicals and suppliers of other goods and services to the generic drug industry. Appointed to the position by the AAM Board in summer 2015, Chip is responsible for ensuring that the association fulfils its primary mission, which is to improve the lives of patients and consumers by providing timely access to safe, effective and affordable medicines.

Prior to joining AAM, Chip most recently served as Executive Vice President for Advocacy and Member Relations at the Pharmaceutical Research and Manufacturers of America (PhRMA), where he was responsible for leading PhRMA’s federal, state and international government relations and advocacy efforts, in addition to member company recruitment and retention. Prior to joining PhRMA, he was Vice President of Corporate External Relations for AstraZeneca, where he oversaw the company’s government relations, strategic alliances, community relations and employee volunteer efforts. He was a member of AstraZeneca’s Corporate Affairs Leadership team and Vice Chairman of the company’s Political Action Committee. In 2007, Chip was one of the inaugural winners of the AstraZeneca CEO Award, given to global executives who best demonstrate AstraZeneca leadership capabilities in their accomplishments.

Chip earned an undergraduate degree in Accounting from the University of Delaware, and a Juris Doctor from the University of Baltimore School of Law. He is a licensed attorney in Maryland, Virginia and the District of Columbia. He currently serves on the board of directors for the Washington, D.C. area Chapter of Autism Speaks, the University of Delaware Alumni Association and the St. Mary’s High School Royal Blue Club, and the member advisory board for the National Journal.
See more

Articles: Chester “Chip” Davis, Jr

Opportunities to Fix Medicare Part D

USA / The Association for Accessible Medicines’ Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic and biosimilar competition and therefore increase patient access to more affordable medicines.   In this election year I hope that the candidates will lay out their solutions to expand access to quality,…

180-Day Exclusivity: The Key Ingredient in Hatch-Waxman

Opinion / The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act.   A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the sugar in the Hatch-Waxman cupcake,…

Biosimilars Work. Why Aren’t They Taking Off in the US?

USA / The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs have the potential to transform…

After the Prescription Is Written, Another Challenge: Abandonment

Opinion / The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug prices and reducing abandonment rates.   Generic and biosimilar prescription drugs manufactured by member companies of the Association for Accessible Medicines (AAM) play an integral role in the health of Americans. This achievement…

Making the Case for Competition — With Data

Pricing / Generic drugs foster competition in the pharmaceutical market. Chester “Chip” Davis, Jr.  of the Association for Accessible Medicines (AAM) reveals the data behind generic competition and elaborates on opportunities for further savings.    The American public is clamoring for systemic changes to address skyrocketing drug prices. Specialty drugs—a growing category that includes biologics and other…

An International Approach to Boosting the US Biosimilars Market

USA / Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA.   Advancements in biologic research and development have brought forth life-saving treatments for patients with cancer as well as such chronic illnesses such as multiple sclerosis,…

The US Generic Drug Supply Chain: “Standardized, Transparent & Dynamic”

Opinion / Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics supply chain is standardized, transparent and dynamic, helping save the US healthcare system trillions of dollars.   Savings have totaled USD 2 trillion in the…

USA: The Biosimilars Trade Opportunity

USA / Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours.   An American president determined to seal a trade deal. A newly elected Democratic majority with an agenda of its own.…

Generics: Pioneered by Women

USA / As part of Women’s History Month, Chip Davis, president and CEO of the Association for Accessible Medicines highlights some of the most outstanding women that have worked in the generic pharmaceutical industry throughout history and pinpoints the women shaping today’s landscape for affordable and accessible medicines.   As we wrap up Women’s History Month, I…

The Future of Biosimilars in the USA

Opinion / Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize its full potential.   Europe…

“Restricting Drug Patent Settlements is Bad for US Patients”

Opinion / Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would prohibit generic and biosimilar pharmaceutical…

The Long and Short of Drug Shortages in America

USA / Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) weighs in on the issue of drug shortages in America.    An uncertain environment for generic manufacturers imperils the sustainability of patient access to low-cost generic medicines.   The unavailability of prescription medicines can cause physical suffering, with possible long-term consequences. Across…

How the USA’s CREATES Act Restores Competition to the Pharmaceutical Market

USA / Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) discusses the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES) and how it will improve access to medicines and restore healthy competition to the market.    American taxpayers, along with millions of patients, will benefit from the restoration of healthy…

Jeopardizing US Patients’ Health Is An Unacceptable Trade-Off

Regulation / Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices.    The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens to undermine this commitment.  …

See more